Kymera Therapeutics, Inc. financial data

Symbol
KYMR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 North Beacon Street, 4 Th Floor, Watertown, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 690 % +12.6%
Debt-to-equity 29.1 % +2.9%
Return On Equity -28.9 % +12.9%
Return On Assets -22.4 % +13.5%
Operating Margin -210 % +37.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.8M shares +11.4%
Common Stock, Shares, Outstanding 61.6M shares +11.2%
Entity Public Float 1.01B USD +27.9%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 73.1M shares +25.3%
Weighted Average Number of Shares Outstanding, Diluted 73.1M shares +25.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 88.6M USD +71.4%
Research and Development Expense 209M USD +19.5%
General and Administrative Expense 60.1M USD +22.9%
Operating Income (Loss) -186M USD -7.76%
Income Tax Expense (Benefit) 200K USD
Net Income (Loss) Attributable to Parent -158M USD -0.17%
Earnings Per Share, Basic -2.42 USD/shares +12%
Earnings Per Share, Diluted -2.42 USD/shares +12%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67.6M USD +29.1%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 525M USD +36.3%
Property, Plant and Equipment, Net 51.7M USD +88.2%
Operating Lease, Right-of-Use Asset 48.7M USD -12.5%
Other Assets, Noncurrent 1.89M USD -32.6%
Assets 826M USD +41.9%
Accounts Payable, Current 6.51M USD +73.8%
Accrued Liabilities, Current 23.8M USD +5.74%
Contract with Customer, Liability, Current 19.3M USD -20.8%
Liabilities, Current 62.1M USD +13.8%
Contract with Customer, Liability, Noncurrent 3.19M USD -84.4%
Operating Lease, Liability, Noncurrent 74.8M USD +6.13%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 141M USD -3.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.1M USD +42.3%
Retained Earnings (Accumulated Deficit) -621M USD -34.1%
Stockholders' Equity Attributable to Parent 685M USD +57.3%
Liabilities and Equity 826M USD +41.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.6M USD +9.96%
Net Cash Provided by (Used in) Financing Activities 354M USD +30423%
Net Cash Provided by (Used in) Investing Activities -331M USD -1445%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 61.6M shares +11.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.4M USD +9.78%
Interest Paid, Excluding Capitalized Interest, Operating Activities 49K USD -5.77%
Deferred Tax Assets, Valuation Allowance 162M USD +35.2%
Deferred Tax Assets, Gross 184M USD +46.3%
Operating Lease, Liability 86.2M USD +18%
Depreciation 5.2M USD +52.9%
Payments to Acquire Property, Plant, and Equipment 7.4M USD +84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -156M USD +0.59%
Lessee, Operating Lease, Liability, to be Paid 131M USD +5.9%
Property, Plant and Equipment, Gross 64.2M USD +77.4%
Operating Lease, Liability, Current 11.4M USD +345%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.4M USD +2.42%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.1M USD +5.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44.6M USD -11.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.8M USD +2.42%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 13.2M USD +2.42%
Depreciation, Depletion and Amortization 1.46M USD +66.2%
Deferred Tax Assets, Net of Valuation Allowance 21.7M USD +278%
Share-based Payment Arrangement, Expense 48.9M USD +26.7%